Scrip is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By


With URL, Takeda Looks To Become U.S. Gout Therapy Provider Of Choice

This article was originally published in PharmAsia News

Executive Summary

In purchasing privately held URL for $800 million, Takeda acquires gout drug Colcrys, which it will market alongside Uloric.


Related Content

Regeneron’s Arcalyst Gets Advisory Committee For Niche Gout Indication
Colcrys Promo Eats Pavement As FDA Objects To Ad Of Motorcyclist Holding Teacup
Novartis' Ilaris For Gout: FDA Questions Whether Symptom Relief Is Worth Risks
Hill Democrats Continue Inquiries Into High Prices For New Versions Of Old Drugs; Avanir's Nuedexta And URL Pharma's Colcrys Targeted
As Gout Market Opens Up, Experts Await Therapies To Better Lower Uric Acid


Related Companies




Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts